Concrete pouring
Release time:
2020-07-07
concrete pouring should comply with the corresponding construction specifications, special attention should be paid to:
1, concrete in the construction of water-absorbing objects involved in the corresponding treatment before pouring, in order to avoid concrete moisture absorption, affecting the quality of concrete.
2, concrete should be poured before the initial setting, and there can be no segregation phenomenon, if there is segregation phenomenon, should be re-mixing, before pouring, and pouring process should also avoid segregation phenomenon.
3. When pouring structures such as columns, a layer of 50-100mm cement mortar (the mix ratio is the same as that in concrete) shall be poured at the bottom to avoid honeycomb pitting.
4, concrete pouring, should be carried out in layers according to the structural requirements, with pouring and tamping.
5. The overall concrete pouring of general structures shall be carried out continuously as much as possible to avoid intermittent construction. In the initial stage after concrete pouring, the concrete shall be protected from vibration or impact.
7. When making cement floor, roof platform and other parts, attention should be paid to the plastering operation. Generally, it should be plastered many times until there is no bleeding on the surface, but dry powder should not be sprinkled and cured in time during the plastering process.
8. In order to prevent early cracks in road construction, attention should be paid to:
①. Under the condition of meeting the design grade of concrete, accurate measurement should be made, excessive cement should not be used, and the unit water consumption of concrete should be mastered to reduce the shrinkage of concrete.
②, do not use high-temperature cement, the cement temperature during site construction should be lower than 70 ℃. In summer construction, the pouring temperature of concrete should be reduced as much as possible, the operation time from the beginning of pouring to the completion of surface finishing should be shortened, and the concrete should be fully cured. Regardless of the circumstances and conditions, the temperature of the concrete mixture shall not exceed 35 ℃. During winter construction, the mixing time should be extended, and the discharge temperature should not be lower than 10 ℃. At the same time, after the construction of pavement concrete, the first three days of maintenance temperature should be maintained above 10 ℃, the next 7 days of maintenance temperature should be maintained above 5 ℃.
③. When using dry aggregate exposed to sunlight for a long time, water shall be fully sprinkled to cool down.
④, the top surface of the base should be fully wet before pouring concrete, or take waterproof measures.
⑤, concrete surface finishing process, to avoid direct sunlight, do not make the temperature rise and dry.
⑥. According to the strength development, master the appropriate time for plate cutting to prevent the concrete slab from breaking.
Peak Cement Implementation GB175-1999 Standard Strength Guarantee Value
| Product Species |
Strength Grade |
Compressive Strength Mpa |
flexural strength Mpa |
||
| 3d |
28d |
3d |
28d |
||
| silicate cement |
42.5R |
25.0 |
48.0 |
4.5 |
7.5 |
| 52.5 |
27.0 |
56.0 |
4.5 |
8.0 |
|
| Ordinary Silicate Cement |
32.5R |
18.0 |
40.0 |
4.0 | #
6.5 |
| 42.5 |
20.0 |
48.0 |
4.0 |
7.5 |
|
| 42.5R |
23.0 |
48. |
4.5 |
7.5 |
|
| 52.5 |
26.0 |
56.0 |
4.5 |
8.0 |
|
| Composite Cement |
32.5R |
18.0 |
40.0 |
4.0 |
6.5 |
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page